高龄晚期胃癌化疗的临床研究  

Clinical study of chemotherapy on aged patients with advanced gastric carcinoma

作　　者：张学梅[1] 佘春燕[1] 许崇安[1] 

机构地区：[1]中国医科大学附属第四医院肿瘤科,辽宁沈阳110032

出　　处：《现代肿瘤医学》2014年第4期857-860,共4页Journal of Modern Oncology

摘　　要：目的:探讨化疗对高龄晚期胃癌患者的疗效与安全性。方法:研究我院88例高龄晚期胃癌初治患者,根据是否接受化疗,分为化疗组43例,对照组45例。化疗组分别应用FOLFOX4方案、CF方案、优福定单药方案、卡培他滨单药方案、多西他赛联合卡培他滨方案,至少完成3个周期化疗;对照组予最佳对症支持治疗。结果:化疗组与对照组有效率分别为44.19%、2.22%,差异有统计学意义(P<0.01);生活质量改善获益分别为83.72%、57.78%,差异有统计学意义(P<0.01);中位疾病进展时间分别为(5.3±1.09)个月、(3.5±0.22)个月,差异有统计学意义(P<0.05);中位生存时间分别为(10.20±1.442)个月、(7.40±0.803)个月,差异有统计学意义(P<0.05)。化疗毒副反应仅有1/43(2.3%)Ⅳ度血液学毒性,经对症治疗后好转。结论:化疗组的有效率、生活质量改善获益率、中位疾病进展时间、中位总生存期均较最佳对症治疗组有显著差异,且毒副反应轻微,患者能耐受治疗,提示对于高龄晚期胃癌患者化疗在延长生存期、提高生活质量等方面明显优于最佳对症支持治疗。Objective：To investigate the effect and the security of chemotherapy on aged patients with advanced gastric cancer. Methods ：All 88 cases of old patients with advanced gastric cancer previously untreated,were divided into chemotherapy group with 43 cases and control group with 45 cases. Chemotherapy group was treated with FOL- FOX4, CF, UFT, capecitabine, docetaxel combined with capecitabine at least 3 cycles. Control group received the best symptomatic and supporting treatment. Results：The effective rates of chemotherapy group and control group were 44. 19% and 2.22% respectively, the difference was statistically significant （P 〈0.01）. Benefit rates of improvement of quality of life were 83.72% and 57.78 % respectively, the difference was statistically significant （P 〈 0.01 ）. The median times of disease progression were （5.3 ± 1.09 ） months and （ 3.5 ± 0.22） months respectively, the difference was statistically significant（P 〈0.05 ）. The median survival times were （10.20 ± 1. 442） months and （ 7.40 ± 0. 803 ） months respectively, the difference was statistically significant（ P 〈 O. 05 ）. The side effect of chemo- therapy was only one（ 2.3% ） case with class IV hematologic toxicity ,which was improved after symptomatic thera- py. Conclusion：The effective rate, benefit rate, the median time of disease progression, and the median survival time of chemotherapy group were all significant than that the best symptomatic treatment group, the side effects were slight, and patients could tolerate the treatment, which suggested that chemotherapy was significantly better than the best symptomatic and supporting treatment in prolonging survival period, improving the quality of life for aged advanced gastric cancer patients.

关 键 词：化学治疗 最佳对症支持治疗 晚期胃癌 

分 类 号：R273[医药卫生—中西医结合]